Nevolat (Liraglutide)

Liraglutide, the active ingredient in Nevolat, is a GLP‑1 receptor agonist presented as a subcutaneous injection for subcutaneous use. It treats type 2 diabetes mellitus and is also indicated for weight management in adults. The product is authorized in the European Union and conforms to EU pharmaceutical standards, working by enhancing glucose‑dependent insulin secretion, suppressing glucagon, and slowing gastric emptying.

GNH USA supplies Nevolat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on reliable cold‑chain logistics.

Nevolat (liraglutide) is used in the management of metabolic disorders that involve impaired glucose regulation and excess body weight.

- Type 2 diabetes mellitus: improves glycemic control and reduces HbA1c levels. - Obesity/weight management: promotes weight loss when combined with diet and exercise. - Cardiovascular risk reduction: lowers incidence of major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.

Liraglutide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Constipation - Headache - Injection site reactions (redness, itching)

Serious or Rare Side Effects: - Pancreatitis - Gallbladder disease (cholelithiasis, cholecystitis) - Severe hypoglycemia (especially with insulin or sulfonylureas) - Acute allergic reactions (anaphylaxis, angioedema) - Thyroid C‑cell tumors (observed in rodent studies) - Acute renal impairment

Before initiating Nevolat, clinicians should consider several precautionary measures to ensure safe use.

- Renal function assessment: evaluate eGFR and adjust use in severe renal impairment. - Pancreatitis monitoring: discontinue if signs of pancreatitis develop. - Thyroid disease evaluation: avoid in patients with medullary thyroid carcinoma or MEN 2. - Gastrointestinal tolerance: start with low dose and titrate to minimize nausea. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Liraglutide can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Concurrent insulin or sulfonylureas: increased risk of severe hypoglycemia. - Other GLP‑1 receptor agonists or DPP‑4 inhibitors: additive glucose‑lowering effects. - Medications that significantly delay gastric emptying: may alter absorption of oral drugs.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR, monitor coagulation. - Oral contraceptives: reduced absorption, consider alternative contraception. - Beta‑blockers: may mask hypoglycemia symptoms, monitor blood glucose. - Lipid‑lowering agents (statins): monitor for potential changes in lipid profile.